Alector
IPO
Breakthroughs come from unexpected places.
- Headquarters
- South San Francisco, California
- Founded
- 2013
- Business Model
- B2B
- Website
- alector.com
- Total Funding
- $162.5M
- Last Round
- $133.0M Series EJul 2018
About
Alector develops therapies to treat neurodegenerative diseases by combining advanced science and technology with expertise in human genetics, neuroscience, and immunology. Their pipeline targets toxic proteins, deficient proteins, and immune/nerve cell function to improve brain health and patient outcomes.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account